Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 11—November 2004
THEME ISSUE
ICEID & ICWID 2004
International Conference on Women and Infectious Diseases (ICWID)

Vaccines for Women Age 50 and Older

Pierce Gardner*Comments to Author  and Sudha Pabbatireddy†
Author affiliations: *National Institutes of Health, Bethesda, Maryland, USA; †Stony Brook University, Stony Brook, New York, USA

Main Article

Figure

Recommended Adult Immunization Schedule, United States, 2003–2004 (12) (footnotes available from http://www.cdc.gov/nip/recs/adult-schedule.htm). This schedule indicates the recommended age groups for routine administration of currently licensed vaccines for persons >19 years of age. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine’s other components are not contraindicated. aOne dose if measles, mumps, or rubella vaccination h

Figure. Recommended Adult Immunization Schedule, United States, 2003–2004 (12) (footnotes available from http://www.cdc.gov/nip/recs/adult-schedule.htm). This schedule indicates the recommended age groups for routine administration of currently licensed vaccines for persons >19 years of age. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine’s other components are not contraindicated. aOne dose if measles, mumps, or rubella vaccination history unreliable; two doses for persons with occupational or other indications.

Main Article

References
  1. Centers for Disease Control and Prevention. Prevention and control of influenza. MMWR Morb Mortal Wkly Rep. 2004;53:1–40.
  2. Thompson  WW, Shay  DK, Weintraub  E, Brammer  L, Cox  N, Anderson  LJ, Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–86. DOIPubMedGoogle Scholar
  3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1–24.PubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehension strategy for eliminating transmission in the United States through universal childhood vaccination; recommendations of the Immunization practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1–25.
  5. Effros  RB. Problems and solutions to the development of vaccines in the elderly. Immunol Allergy Clin North Am. 2003;23:41–55. DOIPubMedGoogle Scholar
  6. Fujihashi  K, Koga  T, McGhee  JR. Mucosal vaccination and immune responses in the elderly. Vaccine. 2000;18:1675–80. DOIPubMedGoogle Scholar
  7. LeMaoult  J, Szabo  P, Weksler  ME. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev. 1997;160:115–26. DOIPubMedGoogle Scholar
  8. Averhoff  F, Mahoney  F, Coleman  P, Schatz  G, Hurwitz  E, Margolis  H, Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1–8. DOIPubMedGoogle Scholar
  9. Hollinger  FB, Hollinger  FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87:36s–40s. DOIPubMedGoogle Scholar
  10. Gilden  D. Herpes zoster with postherpetic neuralgia-persisting pain and frustration. N Engl J Med. 1994;330:932–4. DOIPubMedGoogle Scholar
  11. Levin  M, Murray  M, Rotbart  H, Zerbe  GO, White  CJ, Hayward  AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992;166:253–9. DOIPubMedGoogle Scholar
  12. Recommended adult immunization schedule—United States, 2003–2004. MMWR Morb Mortal Wkly Rep. 2003;52:965–9.
  13. Centers for Disease Control and Prevention. Assessing adult vaccination status at age 50 years [notice to readers]. MMWR Morb Mortal Wkly Rep. 1995;44:561–3.PubMedGoogle Scholar
  14. Patrarca  PA, Weber  JA, Parker  RA, Hall  WN, Kendal  AP, Bregman  DJ, Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA. 1985;253:1136–9. DOIPubMedGoogle Scholar
  15. Arden  NH, Patriarca  PA, Kendal  AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. Presented at Options for the Control of Influenza 1986;155–68.
  16. Monto  AS, Hornbuckle  K, Ohmit  SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001;154:155–60. DOIPubMedGoogle Scholar
  17. Nichol  KL, Nordin  J, Mullooly  J, Lask  R, Fillbrandt  K, Iwane  M, Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–32. DOIPubMedGoogle Scholar
  18. Potter  J, Stott  DJ, Roberts  MA, Elder  AG, O’Donnell  B, Knight  PV, Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1–6. DOIPubMedGoogle Scholar
  19. Carman  WF, Elder  AG, Wallace  LA, McAulay  K, Walker  A, Murray  GD, Effects of influenza vaccination of health-care workers on mortality of elderly people in long term care: a randomised controlled trial. Lancet. 2000;355:93–7. DOIPubMedGoogle Scholar
  20. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003;52(RR-13):1–8.PubMedGoogle Scholar
  21. Marrie  TJ, Durant  H, Yates  L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11:586–99. DOIPubMedGoogle Scholar
  22. Feikin  DR, Schuchat  A, Kolczak  M, Barrett  NL, Harrison  LH, Lefkowitz  L, Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health. 2000;90:223–9. DOIPubMedGoogle Scholar
  23. Jackson  LA, Neuzil  KM, Yu  O, Benson  P, Barlow  WE, Adams  AL, Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747–55. DOIPubMedGoogle Scholar
  24. Koivula  I, Sten  M, Leinonen  M, Makela  PH. Clinical efficacy of pneumococcal vaccine in the elderly a randomized, single-blind population-based trial. Am J Med. 1997;103:281–90. DOIPubMedGoogle Scholar
  25. Christenson  B, Lundbergh  P, Hedlund  J, Ortqvist  A. Effects of a large-scale intervention with Influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001;357:1008–11. DOIPubMedGoogle Scholar
  26. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >65 years—United States, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1019–24.
  27. Jackson  LA, Benson  P, Sneller  VP, Butler  JC, Thompson  RS, Chen  RT, Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281:243–8. DOIPubMedGoogle Scholar
  28. Nuorti  JP, Butler  JC, Farley  MM, Harrison  LH, McGeer  A, Kolczak  MS, Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342:681–9. DOIPubMedGoogle Scholar
  29. Sisk  JE, Whang  W, Butler  JC, Sneller  VP, Whitney  CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 65 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138:960–8.PubMedGoogle Scholar
  30. Gardner  P. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med. 2003;138:999–1000.PubMedGoogle Scholar
  31. Whitney  CG, Farley  MM, Hadler  J, Harrison  LH, Bennett  NM, Lynfield  R, Decline in invasive pneumococcal disease after the introduction of protein-polysaccharider conjugate vaccine. N Engl J Med. 2003;348:1737–46. DOIPubMedGoogle Scholar
  32. Centers for Disease Control. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991;40(RR-10):1–28.PubMedGoogle Scholar
  33. Balestra  DJ, Littenberg  B. Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med. 1993;8:405–12. DOIPubMedGoogle Scholar
  34. Gardner  P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. In: Infectious disease clinics of North America. Vaccine recommendations: challenges and controversies. Volume 15. Philadelphia: WB Saunders; 2001. p. 143–53.
  35. Martin  M, Tsai  TF, Cropp  B, Chang  GJ, Holmes  DA, Tseng  J, Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98–104. DOIPubMedGoogle Scholar
  36. Centers for Disease Control and Prevention. Health information for international travel, 2003–2004. Yellow book. Atlanta: U.S. Department of Health and Human Services, Public Health Services; 2003.

Main Article

Page created: May 04, 2011
Page updated: May 04, 2011
Page reviewed: May 04, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external